Cargando…
Advances in cancer therapy: clinical benefit of new cancer drugs
Autores principales: | Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Michaeli, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333065/ https://www.ncbi.nlm.nih.gov/pubmed/37338507 http://dx.doi.org/10.18632/aging.204839 |
Ejemplares similares
-
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023) -
Testicular cancer follow-up costs in Germany from 2000 to 2015
por: Michaeli, Thomas, et al.
Publicado: (2021) -
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
por: Michaeli, Thomas, et al.
Publicado: (2023) -
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)